rosiglitazone has been researched along with clofibric acid in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beck, KD; Cobb, JE; Correa, ID; Cowan, DJ; Kliewer, SA; Lehmann, JM; Moore, LB; Prakash, SR; Wiethe, RW; Willson, TM | 1 |
| Crestani, M; Fracchiolla, G; Fruchart, JC; Godio, C; Laghezza, A; Lavecchia, A; Loiodice, F; Mitro, N; Novellino, E; Pinelli, A; Staels, B; Tortorella, V | 1 |
| Conte Camerino, D; Fracchiolla, G; Laghezza, A; Lavecchia, A; Loiodice, F; Mazza, F; Montanari, R; Novellino, E; Piemontese, L; Pierno, S; Pochetti, G; Tortorella, P | 1 |
| Ammazzalorso, A; Amoroso, R; Brunetti, L; Bruno, I; Cama, A; Capone, F; Cerchia, C; De Filippis, B; Fantacuzzi, M; Ferrante, C; Florio, R; Giampietro, L; Laghezza, A; Lavecchia, A; Loiodice, F; Maccallini, C; Recinella, L; Tortorella, P; Verginelli, F | 1 |
| Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T | 1 |
| Baldwin, GS; Ford, J; Lachal, S; Shulkes, A | 1 |
| Balasubramani, M; Capps, N; Milles, J; Ramachandran, S; Shetty, C | 1 |
| Fishman, I; Guttmann, H; Keidar, S; Shapira, C; Stam, T | 1 |
8 other study(ies) available for rosiglitazone and clofibric acid
| Article | Year |
|---|---|
The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.
Topics: Animals; Cell Line; Hypoglycemic Agents; Mice; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship; Thiazoles; Transcription Factors | 1996 |
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
Topics: 3T3 Cells; Adipocytes; Animals; Binding Sites; Cell Differentiation; Cell Line, Tumor; Clofibric Acid; Endopeptidase K; Fibroblasts; Humans; Ligands; Mice; Models, Molecular; Phenylpropionates; PPAR alpha; PPAR gamma; Protein Conformation; Quantitative Structure-Activity Relationship; Stereoisomerism; Trypsin | 2005 |
New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
Topics: Animals; Cell Line, Tumor; Chloride Channels; Chlorides; Clofibric Acid; Crystallography, X-Ray; Drug Discovery; Electric Conductivity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligands; Male; Models, Molecular; Molecular Conformation; Muscle, Skeletal; Muscular Diseases; PPAR alpha; PPAR gamma; Propionates; Rats; Rats, Wistar; Rest; Stereoisomerism; Substrate Specificity | 2009 |
Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome.
Topics: | 2019 |
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic | 1999 |
PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells.
Topics: Bezafibrate; Cell Proliferation; Clofibrate; Clofibric Acid; Colorectal Neoplasms; Fenofibrate; Fibric Acids; Gastrins; Gemfibrozil; Humans; Hypolipidemic Agents; Ligands; Peroxisome Proliferator-Activated Receptors; Protein Precursors; Pyrimidines; Radioimmunoassay; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2004 |
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; England; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |